Resource Summary Report

Generated by FDI Lab - SciCrunch.org on Apr 23, 2025

MV4-11

RRID:CVCL_0064
Type: Cell Line

Proper Citation

(RRID:CVCL_0064)

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0064

Proper Citation: (RRID:CVCL_0064)

Sex: Male

Defining Citation: PMID:1423625, PMID:2656885, PMID:3496132, PMID:8353274, PMID:8358709, PMID:9195772, PMID:12529668, PMID:14504097, PMID:14671638, PMID:15843827, PMID:16408098, PMID:19608861, PMID:20215515, PMID:20922763, PMID:21552520, PMID:22460905, PMID:25485619, PMID:25877200, PMID:25984343, PMID:26589293, PMID:27397505, PMID:30285677, PMID:30629668, PMID:30894373, PMID:31068700, PMID:35839778

Comments: Omics: Transcriptome analysis by RNAseq., Omics: Transcriptome analysis by microarray., Omics: SNP array analysis., Omics: shRNA library screening., Omics: DNA methylation analysis., Omics: Deep quantitative phosphoproteome analysis., Omics: Deep exome analysis., Omics: Acetylation analysis by proteomics., Karyotypic information: 48,XY,t(4;11)(q21;q23),+8,+19 (ATCC=CRL-9591)., Characteristics: CSF2 and IL3 dependent., Population: Caucasian., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Name: MV4-11

Synonyms: MV-4-11, MV-4:11, MV4:11, MV 4;11, MV4;11, MV411, MV(4;11), MV4II

Cross References: BTO:BTO_0006413, CLO:CLO_0007906, EFO:EFO_0002242, CLDB:cl3610, CLDB:cl3611, AddexBio:C0003025/4955, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610,

ATCC:CRL-9591, ATCC:HTB-189, BioGRID_ORCS_Cell_line:138, BioSample:SAMN01821582, BioSample:SAMN01821649, BioSample:SAMN03473104, BioSample:SAMN10988366, cancercelllines:CVCL_0064, CCRID:3101HUMSCSP5031, Cell_Model_Passport:SIDM00657, ChEMBL-Cells:CHEMBL3308063, ChEMBL-Targets:CHEMBL613835, CLS:300295, Cosmic:787416, Cosmic:798673, Cosmic:908156, Cosmic:975284, Cosmic:994182, Cosmic:996315, Cosmic:1012104, Cosmic:1037736, Cosmic:1078732, Cosmic:1089516, Cosmic:1127256, Cosmic:1150899, Cosmic:1152712, Cosmic:1181603, Cosmic:1278781, Cosmic:1281340, Cosmic:1308221, Cosmic:1319550, Cosmic:1451846, Cosmic:1476424, Cosmic:1516631, Cosmic:1524837, Cosmic:1623635, Cosmic:1696137, Cosmic:1779133, Cosmic:2131568, Cosmic:2306226, Cosmic:2392908, Cosmic:2393011, Cosmic:2542841, Cosmic:2750867, Cosmic-CLP:908156, DepMap:ACH-000045, DSMZ:ACC-102, DSMZCellDive:ACC-102, EGA:EGAS00001000610, EGA:EGAS00001000978, EGA:EGAS00001002554, GDSC:908156, GEO:GSM236796, GEO:GSM236832, GEO:GSM482560, GEO:GSM887344, GEO:GSM888420, GEO:GSM1374694, GEO:GSM1446746, GEO:GSM1670137, IARC_TP53:21521, IGRhCellID:MV4II, LiGeA:CCLE_055, LINCS_LDP:LCL-1092, Lonza:996, PharmacoDB:MV411_972_2019, PRIDE:PXD030304, Progenetix:CVCL_0064, PubChem_Cell_line:CVCL_0064, TOKU-E:2536, Ubigene:YC-C060, Wikidata:Q54907109

ID: CVCL_0064

Record Creation Time: 20250131T201438+0000

Record Last Update: 20250131T203107+0000

Ratings and Alerts

No rating or validation information has been found for MV4-11.

Warning: Discontinued: ATCC; HTB-189
Omics: Transcriptome analysis by RNAseq., Omics: Transcriptome analysis by microarray., Omics: SNP array analysis., Omics: shRNA library screening., Omics: DNA methylation analysis., Omics: Deep quantitative phosphoproteome analysis., Omics: Deep exome analysis., Omics: Acetylation analysis by proteomics., Karyotypic information: 48,XY,t(4;11)(q21;q23),+8,+19 (ATCC=CRL-9591)., Characteristics: CSF2 and IL3 dependent., Population: Caucasian., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 448 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

Melo Garcia L, et al. (2025) Overcoming CD226-related immune evasion in acute myeloid leukemia with CD38 CAR-engineered NK cells. Cell reports, 44(1), 115122.

Lu MJ, et al. (2024) SLC25A51 decouples the mitochondrial NAD+/NADH ratio to control proliferation of AML cells. Cell metabolism, 36(4), 808.

Howard GC, et al. (2024) Ribosome subunit attrition and activation of the p53-MDM4 axis dominate the response of MLL-rearranged cancer cells to WDR5 WIN site inhibition. eLife, 12.

Chen M, et al. (2024) Metformin synergizes with gilteritinib in treating FLT3-mutated leukemia via targeting PLK1 signaling. Cell reports. Medicine, 5(7), 101645.

Qiao X, et al. (2024) Diversifying the anthracycline class of anti-cancer drugs identifies aclarubicin for superior survival of acute myeloid leukemia patients. Molecular cancer, 23(1), 120.

Caulier B, et al. (2024) CD37 is a safe chimeric antigen receptor target to treat acute myeloid leukemia. Cell reports. Medicine, 5(6), 101572.

Coleman DJL, et al. (2024) Pharmacological inhibition of RAS overcomes FLT3 inhibitor resistance in FLT3-ITD+ AML through AP-1 and RUNX1. iScience, 27(4), 109576.

Lee JK, et al. (2024) Pim Kinase Inhibitors Increase Gilteritinib Cytotoxicity in FLT3-ITD Acute Myeloid Leukemia Through GSK-3? Activation and c-Myc and Mcl-1 Proteasomal Degradation. Cancer research communications, 4(2), 431.

Diepstraten ST, et al. (2024) Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers. Cancer cell, 42(5), 850.

Wang X, et al. (2024) LncRNA IRAIN overcomes imatinib resistance in chronic myeloid leukemia via NF-?B/CD44 pathway inhibition. iScience, 27(6), 109851.

Howard GC, et al. (2024) Ribosome subunit attrition and activation of the p53-MDM4 axis dominate the response of MLL-rearranged cancer cells to WDR5 WIN site inhibition. bioRxiv : the preprint server for biology.

Li Y, et al. (2024) The predictive value of BTG1 for the response of newly diagnosed acute myeloid leukemia to decitabine. Clinical epigenetics, 16(1), 16.

Kansy AG, et al. (2024) Pharmacological degradation of ATR induces antiproliferative DNA replication stress in leukemic cells. Molecular oncology, 18(8), 1958.

Guo HZ, et al. (2024) A CD36-dependent non-canonical lipid metabolism program promotes

immune escape and resistance to hypomethylating agent therapy in AML. Cell reports. Medicine, 5(6), 101592.

Sun YM, et al. (2024) lncRNAs maintain the functional phase state of nucleolar prion-like protein to facilitate rRNA processing. Molecular cell, 84(24), 4878.

Do BT, et al. (2024) Nucleotide depletion promotes cell fate transitions by inducing DNA replication stress. Developmental cell, 59(16), 2203.

Lai J, et al. (2024) ULK2 Is a Key Pro-Autophagy Protein That Contributes to the High Chemoresistance and Disease Relapse in FLT3-Mutated Acute Myeloid Leukemia. International journal of molecular sciences, 25(1).

Bianchi M, et al. (2024) The CD33xCD123xCD70 Multispecific CD3-Engaging DARPin MP0533 Induces Selective T Cell-Mediated Killing of AML Leukemic Stem Cells. Cancer immunology research, 12(7), 921.

Lee S, et al. (2024) B7H6 is the predominant activating ligand driving natural killer cell-mediated killing in patients with liquid tumours: evidence from clinical, in silico, in vitro, and in vivo studies. EBioMedicine, 110, 105459.

Wang P, et al. (2024) Foretinib Is Effective in Acute Myeloid Leukemia by Inhibiting FLT3 and Overcoming Secondary Mutations That Drive Resistance to Quizartinib and Gilteritinib. Cancer research, 84(6), 905.